Navigation Links
ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
Date:5/16/2008

f a single dose of ANX-530 was a secondary objective. In the first week, patients were dosed with either ANX-530 or Navelbine, and after a washout period, were dosed with the opposite drug during the second week of treatment. Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine.

ADVENTRX intends to submit to the U.S. Food and Drug Administration (FDA) a Section 505(b)(2) NDA for ANX-530 around the end of 2008.

About ANX-530 (vinorelbine emulsion)

ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non- small cell lung cancer and advanced or metastatic breast cancer. Worldwide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million.

Navelbine and its generic equivalents are often associated with injection site reactions, including phlebitis, erythema and pain at the site of injection. Studies have shown these reactions occur in approximately one-third of patients, with 5% of the reactions categorized as severe. ANX-530 is designed to reduce the incidence and severity of these injection site reactions. The Company's formulation emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed protect the venous endothelium during administration into a peripheral vein, thereby reducing irritation associated with administration of the drug.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing p
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
3. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
4. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
10. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... OTTAWA , Dec. 24, 2014 /CNW/ - ... Superburn" is being recalled after Health Canada tests confirmed ... serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire ... is recalling the product from retail stores across ... body building purposes, including for weight loss and increased ...
(Date:12/24/2014)... 24, 2014  Novastem, a leader in regenerative ... in its study for ischemic stroke at Clinica ... ischemic strokes account for 87 percent of all ... in the study, entitled "Internal Research Protocol in ... Stem Cells and Intrathecal Administration of Neural Stem ...
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... CeNeS Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical ... the respected scientific,journal 'Synapse'* on its Phase II ... as a potential treatment for neuropathic,pain. The independent ... undertaken with CNS 5161. , In the study ...
... in Humans of CTI's,Programmable, Pulsatile, Passive Transdermal ... TRENTON, N.J., May 03, 2007 /PRNewswire/,-- Chrono ... of its first phase human clinical trial ... ChronoDose(TM). CTI intends to publish this,clinical data ...
Cached Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in Abilene, ... Ferguson, Missouri unrest. Yisrayl starts his letter by showing the ... has only increased. , He continues in his letter ... is a very specific reason for mankind and covers those ... of rules, or Laws that if followed would ensure that ...
(Date:12/26/2014)... London, England (PRWEB) December 26, 2014 ... to take place March 24-28, 2015 in Rome, Italy ... years' line-up includes workshops on a wide ... insomnia, as well as peak performance training in athletes. ... from around the world. , Biofeedback monitoring allows clients ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... 26, 2014 India Network Foundation, a ... the USA, announced today a new version of “ ... choosing the right plan for their visiting parents. The ... of the selection process when choosing an insurance plan ... with only a few clicks. Many elderly Asian Indian ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3
... report , THURSDAY, April 15 (HealthDay News) -- ... by several common bacteria, including the most virulent form of ... often acquired from oysters which can cause severe illness or ... infection have remained flat in recent years. , "Overall, this ...
... says back disorders in the working population are among ... world. Disc degeneration is the main suspected origin of ... surgery. But Videman, a researcher in the University of ... common perception that disc degeneration is caused by physical ...
... associated with lower lung function and greater medication use in ... In a paper published online this week in the ... and his colleagues also reported that vitamin D enhances the ... , "Asthmatic children in our study who had low levels ...
... ... senior consultant specializing in managed care, prevention planning and publicly funded health care services ... ... to announce that Maureen Hanrahan has joined the company as a senior consultant specializing ...
... ... for the amount of $34,000.00. , ... Bedford, MA (PRWEB) April, 15, 2010 -- The law firm of Dussault and Zatir settled out ... was injured while on the job while working as a truck-cleaner. The employee was in ...
... condition leaves many undiagnosed, , THURSDAY, April 15 (HealthDay ... detect cases of chlamydia in young men who see ... They say that many urologists are ignoring guidelines on ... which causes inflammation of the testicle and the epididymis, ...
Cached Medicine News:Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 3Health News:Low vitamin D levels associated with more asthma symptoms and medication use 2Health News:Hanrahan Joins ArpegioHealth Consulting Firm 2
For the quantitative in vitro determination of CK-MB in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
Medicine Products: